30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
- Poster presentation
- Open Access
- Published:
Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
Journal for ImmunoTherapy of Cancer volume 3, Article number: P134 (2015)
Background
About 50% of melanoma (MM) have BRAF V600 mutation and BRAF inhibitors, such as vemurafenib and dabrafenib, have shown an high response rate (RR) and overall survival (OS) improvement in BRAF-mutated MM patients (pts). Pembrolizumab, a monoclonal antibody anti-PD-1, has shown a significant improvement in RR and OS as well, in both MM pts naïve and previously treated with ipilimumab. As an immunotherapy, pembrolizumab should not be affected by BRAF mutational status and the aim of our analysis is to verify whether pembrolizumab is active regardless the BRAF mutational status .
Methods
Inside the expanded access program (EAP), pembrolizumab was given in pts progressing after ipilimumab at dosage of 2 mg/kg every 3 weeks until PD or unacceptable toxicity. At our Institution 47 pts (25M, 22F) were treated. The median age was 49 years (range 28-70). All pts were stage M1c. 40 (85.1%) pts had cutaneous MM, 5 (10.6%) had ocular MM and 2 (4.3%) mucosal MM. 16 out of 47 (34%) had BRAF V600 mutation, and all mutated pts were previously treated with BRAF inhibitors as per protocol. In this retrospective analysis we evaluated the correlation between BRAF mutational status and response to pembrolizumab.
Results
Data on RR and progression free survival (PFS) are available for all 47 pts enrolled in the EAP. From this analysis we excluded ocular MM because it's considered a distinct entity with a different biology. Among the 16/42 (38,1%) pts with BRAF mutation, RR was of 12.5% (2/16) compared with a RR of 36.4% (9/26) observed in BRAF wild-type cohort. The difference was not statistically significant (p 0.16). Disease control rate (DCR) in pts with BRAF mutation resulted 18.6% (3/16) compared with 65.4% DCR (17/26) of BRAF wild-type cohort. The difference was statistically significant (p 0.005). Median PFS of BRAF mutated pts was 3 months (range 2.3 – 3.7), while was not reached (2 – 8+) in BRAF wild-type cohort. The difference resulted statistically significant (p 0.001).
Conclusions
Previous BRAF inhibitors treatment may affect response to pembrolizumab. Further studies are needed to verify this very preliminary observation.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Simeone, E., Grimaldi, A.M., Festino, L. et al. Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients. j. immunotherapy cancer 3 (Suppl 2), P134 (2015). https://doi.org/10.1186/2051-1426-3-S2-P134
Published:
DOI: https://doi.org/10.1186/2051-1426-3-S2-P134
Keywords
- Melanoma
- Overall Survival
- Progression Free Survival
- High Response Rate
- Melanoma Patient